Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
praliciguat · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Healthy Male Volunteers | EXPERIMENTAL | Single oral dose of \[14C\]-praliciguat |
| Name | Type | Description |
|---|---|---|
| [14C]-praliciguat | DRUG | 10 mg praliciguat containing approximately 500 μCi of \[14C\]-praliciguat |
Inclusion Criteria: * Males of any race, between 18 and 55 years of age, inclusive * Body mass index between 18 and 32 kg/m2, inclusive * Subject is in good health and has no clinically significant findings on physical examination * Men must agree to use protocol-specified contraception and also to...
Praliciguat is an investigational small molecule being developed by Cyclerion Therapeutics, Inc. (CYCN). It is currently in Phase 1 clinical development. The drug has been studied in healthy volunteers, with one completed trial involving 8 participants.
Praliciguat is being studied for use in healthy volunteers. It is an investigational drug in Phase 1 clinical development, meaning it has not been approved for any medical condition. The completed trial focused on healthy male volunteers to study the drug's absorption, metabolism, and excretion.
Praliciguat is developed by Cyclerion Therapeutics, Inc., a biopharmaceutical company traded under the ticker symbol CYCN. The company is conducting clinical research on this investigational small molecule drug.
Praliciguat is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and there are no active trials currently listed for this drug.
Praliciguat has one completed clinical trial, NCT03818295, titled "A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Praliciguat in Healthy Male Volunteers." This Phase 1 study enrolled 8 healthy male participants in the United States and was not randomized or blinded.